Clinical trial NCT05081557: A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Official title: Real World Utilization of Upadacitinib in Adult and Adolescent Patients Living With Moderate to Severe Atopic Dermatitis (AD-VISE)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Atopic Dermatitis
Keywords: Atopic Dermatitis
Atopic Eczema
Upadacitinib
RINVOQ
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2021-10-18
Enrollment: 873
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adolescents (12-17 years of age at baseline) and adults (\>=18 years of age at baseline), with a physician-confirmed diagnosis of atopic dermatitis (AD), who are prescribed upadacitinib according to the local label and local practice.

Brief summary: Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns and outcomes with upadacitinib in a real-world setting. Therefore, the purpose of this observational study is to help inform real-world usage patterns regarding the safety and effectiveness and duration of response of upadacitinib in adolescent and adult AD participants \>=12 years old in the real-world setting.

Upadacitinib is an approved drug being developed for the treatment of AD. Around 975 adolescent and adult participants who are prescribed upadacitinib for the treatment of AD in routine clinical practice will be enrolled worldwide.

Participants will receive oral upadacitinib as prescribed by their physician. Data from these participants will be collected for approximately 2 years.

There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.


Eligibility criteria: Inclusion Criteria:

* Physician confirmed diagnosis of atopic dermatitis (AD) or atopic eczema at baseline.
* Symptom onset \>=1-year prior to baseline.
* Initiation of upadacitinib treatment for AD is indicated and prescribed per local label.
* The decision to prescribe UPA is made prior to and independently of study participation.
* Medical and medication history available for previous 6 months.
* Participants who can understand the questionnaires, with parental support as required for adolescents.
* Participants who are able to understand and communicate with the investigator and comply with the requirements of the study.
* Participants who are willing and able to participate in the collection of patient-reported data via cloud-based mobile application using a smart device (i.e., tablet).
* Participants who are willing and able to complete the patient-reported questionnaires.

Exclusion Criteria:

- Participants who are currently participating in interventional research (not including non-interventional study, post-marketing observational study, or registry participation).

Primary outcomes:
measure: Upadacitinib (UPA) Utilization Patterns
timeFrame: Up to Approximately 24 Months
measure: Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) 0/1
timeFrame: Month 4
measure: vIGA-AD 0/1 Among Participants Who Achieved vIGA-AD 0/1 at Month 4
timeFrame: Month 24
Secondary outcomes:
measure: Modification of UPA or Concomitant AD Therapy and Associated Timing, Reasons
timeFrame: Month 24
measure: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75
timeFrame: Up to Approximately 24 months
measure: Percentage of Participants Achieving EASI 90
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving EASI 100
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving EASI <=1
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving EASI <=5.9
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving EASI <=7
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving vIGA-AD 0/1
timeFrame: Up to Approximately 24 Months (Excluding Month 4 - Primary Outcome)
measure: Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) 0/1
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving WP-NRS <=3
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving WP-NRS reduction >=4
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving Patient Oriented Eczema Measurement (POEM) Score <=2
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving POEM <=7
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving POEM Reduction >=4
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0/1
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving DLQI Score <=5
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving DLQI reduction >=4
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving Atopic Dermatitis Control Tool (ADCT) <7 (control)
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving ADCT reduction >=5
timeFrame: Up to approximately 24 Months
measure: Percentage of Participants who are "Extremely Satisfied" or "Very Satisfied" with their AD Treatment using the Patient Global Impression of Treatment for Atopic Dermatitis (PGIT-AD)
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Remaining on Upadacitinib Once Daily
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving EASI 75 Among Participants Who Achieved EASI 75 at Month 4
timeFrame: Up to Approximately 24 months
measure: Percentage of Participants Achieving EASI 90 Among Participants Who Achieved EASI 90 at Month 4
timeFrame: Up to Approximately 24 months
measure: Percentage of Participants Achieving EASI 100 Among Participants Who Achieved EASI 100 at Month 4
timeFrame: Up to Approximately 24 months
measure: Percentage of Participants Achieving vIGA-AD 0/1 Among Participants Who Achieved vIGA-AD at Month 4
timeFrame: Up to Approximately 24 Months (Excluding Month 24 - Primary Outcome)
measure: Percentage of Participants Achieving WP-NRS 0/1 Among Participants Who Achieved WP-NRS 0/1 at Month 4
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving DLQI Score of 0/1 Among Participants Achieving DLQI Score of 0/1 at Month 4
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving ADCT Reduction <7 Among Participants Who Achieved ADCT Reduction <7 at Month 4
timeFrame: Up to approximately 24 Months
measure: Absolute Score and Change from Baseline in EASI
timeFrame: Up to Approximately 24 months
measure: Absolute Score and Change from Baseline in vIGA-AD
timeFrame: Up to Approximately 24 months
measure: Absolute Score and Change from Baseline in Body Surface Area (BSA)
timeFrame: Up to Approximately 24 Months
measure: Absolute Score and Change from Baseline in WP-NRS
timeFrame: Up to Approximately 24 Months
measure: Absolute Score and Change from Baseline in POEM
timeFrame: Up to Approximately 24 Months
measure: Absolute Score and Change from Baseline in DLQI
timeFrame: Up to Approximately 24 Months
measure: Absolute Score and Change from Baseline in ADCT
timeFrame: Up to Approximately 24 months
measure: Absolute Score and Change from Baseline in PGIT-AD
timeFrame: Up to Approximately 24 Months
measure: Change from Baseline in Flare Frequency and Duration
timeFrame: Up to Approximately 24 Months
measure: Change from Baseline in the Number of AD-Related Physician Office or Hospital Visits
timeFrame: Up to Approximately 24 Months
measure: Absolute Score and Change from Baseline in Work Productivity and Activity Impairment Index for Atopic Dermatitis (WPAI-AD)
timeFrame: Up to Approximately 24 Months
measure: Time to Achieve EASI 75
timeFrame: Up to Approximately 24 months
measure: Time to Achieve EASI 90
timeFrame: Up to Approximately 24 months
measure: Time to Achieve EASI 100
timeFrame: Up to Approximately 24 months
measure: Time to Achieve vIGA-AD 0/1
timeFrame: Up to Approximately 24 Months
measure: Time to Achieve WP-NRS 0/1
timeFrame: Up to Approximately 24 Months
measure: Time to Achieve DLQI Score of 0/1
timeFrame: Up to Approximately 24 Months
measure: Time to Achieve POEM <=2
timeFrame: Up to Approximately 24 Months
measure: Time to Achieve ADCT <7
timeFrame: Up to Approximately 24 Months
measure: Time-Weighted EASI Score
timeFrame: Up to Approximately 24 Months
measure: Time-Weighted vIGA-AD Score
timeFrame: Up to Approximately 24 Months
measure: Time-Weighted WP-NRS Score
timeFrame: Up to Approximately 24 Months
measure: Time-Weighted DLQI Score
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving Treatment Target EASI <8
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving Treatment Target DLQI <=5
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving Treatment Target WP-NRS <=4
timeFrame: Up to Approximately 24 Months
measure: Percentage of Participants Achieving Combined Treatment Targets of EASI <8, DLQI <=5, and WP-NRS <=4
timeFrame: Up to Approximately 24 Months
Other outcomes:
Locations:
city: Pilar
country: Argentina
facility: Hospital Universitario Austral /ID# 241607
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Buenos Aires Skin /ID# 241606
state: Ciudad Autonoma De Buenos Aires
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: CEDIC Centro de Investigaciones Clinicas /ID# 241605
state: Ciudad Autonoma De Buenos Aires
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Instituto de Neumonologia y Dermatologia /ID# 241604
state: Ciudad Autonoma De Buenos Aires
city: Rosario
country: Argentina
facility: Centro Respiratorio Infantil /ID# 241609
state: Santa Fe
city: Caba
country: Argentina
facility: Hospital Italiano /ID# 241608
city: Miranda
country: Australia
facility: Kingsway Dermatology & Aesthetics /ID# 242276
state: New South Wales
city: Woolloongabba
country: Australia
facility: Veracity Clinical Research /ID# 242275
state: Queensland
city: Bedford, Park
country: Australia
facility: Flinders Medical Centre /ID# 242162
state: South Australia
city: East Melbourne
country: Australia
facility: Sinclair Dermatology - Melbourne /ID# 242163
state: Victoria
city: Victoria Park
country: Australia
facility: Burswood Dermatology /ID# 243767
state: Western Australia
city: Newtown
country: Australia
facility: Sydney Skin /ID# 242277
city: Linz
country: Austria
facility: Ordensklinikum Linz GmbH Elisabethinen /ID# 246565
state: Oberoesterreich
city: Wels
country: Austria
facility: Klinikum Wels-Grieskirchen GmbH /ID# 247369
state: Oberoesterreich
city: Nenzing
country: Austria
facility: Dr. Achim Schneeberger /ID# 247370
state: Vorarlberg
city: Vienna
country: Austria
facility: Medizin am Hauptbahnhof /ID# 246567
state: Wien
city: Vienna
country: Austria
facility: EZW HAUT Entzuendungszentrum Wien /ID# 246566
state: Wien
city: Edmonton
country: Canada
facility: Rejuvenation Dermatology - Edmonton Downtown /ID# 240377
state: Alberta
city: Winnipeg
country: Canada
facility: Winnipeg Clinic /ID# 239603
state: Manitoba
city: Fredericton
country: Canada
facility: Dr. Irina Turchin PC Inc. /ID# 240358
state: New Brunswick
city: St. John's
country: Canada
facility: Karma Clinical Trials /ID# 239602
state: Newfoundland and Labrador
city: St. John's
country: Canada
facility: NewLab Clinical Research Inc. /ID# 239600
state: Newfoundland and Labrador
city: Cobourg
country: Canada
facility: Dr Melinda Gooderham Medicine Profession /ID# 239745
state: Ontario
city: Hamilton
country: Canada
facility: Lima's Excellence in Allergy and Dermatology Research Inc /ID# 239854
state: Ontario
city: Markham
country: Canada
facility: Lynde Institute for Dermatology /ID# 240025
state: Ontario
city: North York
country: Canada
facility: Gordon Sussman Medicine Professional Corporation /ID# 243383
state: Ontario
city: Ottawa
country: Canada
facility: JRB Research /ID# 241862
state: Ontario
city: Richmond Hill
country: Canada
facility: Dr. Michael Cecchini Medicine Professional Corporation /ID# 239605
state: Ontario
city: Sudbury
country: Canada
facility: Dr. Lyne Giroux Medicine Professional Corporation /ID# 240084
state: Ontario
city: Toronto
country: Canada
facility: North York Research Inc /ID# 253191
state: Ontario
city: Toronto
country: Canada
facility: Canadian Dermatology Centre /ID# 240585
state: Ontario
city: Toronto
country: Canada
facility: Centricity Research - Toronto Dermatology /ID# 241019
state: Ontario
city: Whitby
country: Canada
facility: Dr Maksym Breslavets Medicine Professional Corporation /ID# 239741
state: Ontario
city: Laval
country: Canada
facility: Clinique D /ID# 239601
state: Quebec
city: Laval
country: Canada
facility: Roula Rassi MD Inc /ID# 252562
state: Quebec
city: Saint-Jerome
country: Canada
facility: Dre Angelique Gagne-Henley M.D. inc. /ID# 239604
state: Quebec
city: St-Jean Sur Le Richelieu
country: Canada
facility: Clinique de Dermatologie du Haut-Richelieu /ID# 239742
state: Quebec
city: Ceske Budejovice
country: Czechia
facility: Nemocnice Ceske Budejovice a.s. /ID# 246479
state: Praha 17
city: Prague
country: Czechia
facility: Nemocnice Na Bulovce /ID# 246482
state: Stredocesky Kraj
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc /ID# 251177
city: Prague
country: Czechia
facility: Duplicate_Fakultni Nemocnice v Motole /ID# 246480
city: Praha
country: Czechia
facility: Fakultni nemocnice Kralovske Vinohrady /ID# 250792
city: Patras
country: Greece
facility: Olympion General Clinic /ID# 261694
state: Achaia
city: Amaroussio
country: Greece
facility: Hygeia Hospital /ID# 254188
state: Attiki
city: Athens
country: Greece
facility: 401 GSNA - 401 Army General Hospital /ID# 253222
state: Attiki
city: Athens
country: Greece
facility: 401 GSNA - 401 Army General Hospital /ID# 253228
state: Attiki
city: Athens
country: Greece
facility: University General Hospital Attikon /ID# 253221
state: Attiki
city: Athens
country: Greece
facility: General Hospital Andreas Syggros /ID# 253220
state: Attiki
city: Piraeus
country: Greece
facility: Tzaneio general hospital of Piraeus /ID# 253223
state: Attiki
city: Thessaloniki
country: Greece
facility: Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 253225
state: Evrytania
city: Thessaloniki
country: Greece
facility: Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 253230
state: Evrytania
city: Thessaloniki
country: Greece
facility: Papageorgiou General Hospital /ID# 253226
state: Evrytania
city: Athens
country: Greece
facility: Naval Hospital of Athens /ID# 253229
city: Larissa
country: Greece
facility: University General Hospital of Larissa /ID# 254216
city: Debrecen
country: Hungary
facility: Debreceni Egyetem-Klinikai Kozpont /ID# 239949
state: Hajdu-Bihar
city: Pecs
country: Hungary
facility: Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 239950
state: Nograd
city: Szombathely
country: Hungary
facility: Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 239951
state: Vas
city: Budapest
country: Hungary
facility: Semmelweis Egyetem /ID# 239948
city: Szeged
country: Hungary
facility: Szegedi Tudományegyetem /ID# 239947
city: Afula
country: Israel
facility: HaEmek Medical Center /ID# 247834
state: H_efa
city: Haifa
country: Israel
facility: Rambam Health Care Campus /ID# 244904
state: H_efa
city: Haifa
country: Israel
facility: Maccabi /ID# 252598
state: H_efa
city: Ashkelon
country: Israel
facility: The Edith Wolfson Medical Center /ID# 244902
state: HaDarom
city: Rehovot
country: Israel
facility: Duplicate_Kaplan Medical Center /ID# 244903
state: HaMerkaz
city: Rehovot
country: Israel
facility: Leumit /ID# 260022
state: HaMerkaz
city: Safed
country: Israel
facility: ZIV Medical Center /ID# 244908
state: HaTsafon
city: Ramat Gan
country: Israel
facility: Sheba Medical Center /ID# 244905
state: Tel-Aviv
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center /ID# 244907
state: Tel-Aviv
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center /ID# 247833
state: Yerushalayim
city: Genoa
country: Italy
facility: Ospedale San Martino /ID# 255081
state: Genova
city: Milan
country: Italy
facility: IRCCS Ospedale San Raffaele /ID# 255285
state: Milano
city: Torino
country: Italy
facility: AOU Citta della Salute e della Scienza di Torino /ID# 254615
state: Piemonte
city: Cava De' Tirreni
country: Italy
facility: AOU San Giovanni e Ruggi Salerno - Presidio Ospedaliero S.M.I. dell'Olmo /ID# 254689
state: Salerno
city: Bari
country: Italy
facility: A.O.U. Consorziale Policlinico di Bari /ID# 254612
city: Catania
country: Italy
facility: AOU Policlinico G. Rodolico - San Marco /ID# 255707
city: Messina
country: Italy
facility: AOU Gaetano Martino /ID# 255080
city: Novara
country: Italy
facility: Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 254613
city: Roma
country: Italy
facility: Fondazione Policlinico Universitario Campus Bio-Medico /ID# 255283
city: Vicenza
country: Italy
facility: Azienda ULSS 8 Berica /ID# 255011
city: Guadalajara
country: Mexico
facility: Centro de Investigacion Biologica y Terapia Avanzada SC (CIMBYTA) /ID# 243820
state: Jalisco
city: Guadalajara
country: Mexico
facility: Centro Dermatologico Del Country S de Rl de Cv /Id# 243818
state: Jalisco
city: Guadalajara
country: Mexico
facility: Grupo Clinico Catei Sociedad Civil /Id# 243809
state: Jalisco
city: Monterrey
country: Mexico
facility: Welsh Derm Centro de Especialidades Medicas /Id# 268403
state: Nuevo Leon
city: Monterrey
country: Mexico
facility: Consultorio Medico Privado Alejandra Macias Weinmann /Id# 244159
state: Nuevo Leon
city: San Pedro Garza García
country: Mexico
facility: Clinica Dermassad /Id# 264048
state: Nuevo Leon
city: Oaxaca de Juárez
country: Mexico
facility: Consultorio Medico Privado Cipactli Ariel Navarro Hernandez /Id# 244165
state: Oaxaca
city: San Andrés Cholula
country: Mexico
facility: Consultorio Medico Privado Yuri Igor Lopez Carrera /Id# 244164
state: Puebla
city: Mérida
country: Mexico
facility: Consultorio Privado Leslie Lourdes Rodriguez /Id# 243819
state: Yucatan
city: Ciudad de Mexico
country: Mexico
facility: Consultorio Medico Privado Desiree Larenas Linnemann /Id# 244150
city: Mexico City
country: Mexico
facility: Centro Especializado en Diabetes, Obesidad y Prevencion de Enfermedades Cardiova /ID# 243856
city: Toluca
country: Mexico
facility: Neki Servicios Medicos Profesionales S D Rl de Cv /Id# 243817
city: Lodz
country: Poland
facility: Dermoklinika Medical Center /ID# 251249
state: Lodzkie
city: Lublin
country: Poland
facility: Luxderm Specjalistyczny Gabinet Dermatologiczny, /ID# 253106
state: Lubelskie
city: Cracow
country: Poland
facility: Maciej Pastuszczak Indywidualna Praktyka Lekarska /ID# 253105
state: Malopolskie
city: Warszawa
country: Poland
facility: Panstwowy Instytut Medyczny MSWiA w Warszawie /ID# 252447
state: Mazowieckie
city: Warszawa
country: Poland
facility: Prywatna Praktyka Lekarska Witold Owczarek /ID# 252448
state: Mazowieckie
city: Rzeszow
country: Poland
facility: KSW nr1 w Rzeszowie /ID# 251251
state: Podkarpackie
city: Chelyabinsk
country: Russian Federation
facility: Chelyabinsk Regional Clinical Dermatovenerologic Dispensary /ID# 248262
state: Chelyabinskaya Oblast
city: Krasnodar
country: Russian Federation
facility: Clinical Dermatovenerology Dispensary /ID# 245225
state: Krasnodarskiy Kray
city: Petrozavodsk
country: Russian Federation
facility: Republican hospital named after V.A. Baranov /ID# 245230
state: Kurskaya Oblast
city: Moscow
country: Russian Federation
facility: National Research Center Institute of Immunology of the FMBA of Russia /ID# 245221
state: Moskva
city: Ryazan
country: Russian Federation
facility: Research and Clinical Center for Hematology, Oncology and Immunology, Ryazan Sta /ID# 245220
state: Ryazanskaya Oblast
city: Stavropol
country: Russian Federation
facility: LLC Scientific Medical Center for General Therapy and Pharmacology /ID# 245229
state: Stavropol Skiy Kray
city: Kazan
country: Russian Federation
facility: LLC Medical Center ABC of Health /ID# 244816
state: Tatarstan, Respublika
city: Badalona
country: Spain
facility: Hospital Universitario Germans Trias i Pujol /ID# 248512
state: Barcelona
city: L'Hospitalet de Llobregat
country: Spain
facility: Hospital Universitari de Bellvitge /ID# 248513
state: Barcelona
city: Terrassa
country: Spain
facility: Hospital Universitari Mútua Terrassa /ID# 254292
state: Barcelona
city: Logroño
country: Spain
facility: Hospital San Pedro /ID# 248538
state: La Rioja
city: Las Palmas de Gran Canaria
country: Spain
facility: Hospital Universitario Dr. Negrin /ID# 248533
state: Las Palmas
city: Cartagena
country: Spain
facility: Hospital Santa María del Rosell /ID# 251956
state: Murcia
city: San Cristóbal de La Laguna
country: Spain
facility: Hospital Universitario Canarias /ID# 251957
state: Santa Cruz De Tenerife
city: Bilbao
country: Spain
facility: Hospital Universitario Basurto /ID# 248508
state: Vizcaya
city: Barcelona
country: Spain
facility: Hospital Parc de Salut del Mar /ID# 258675
city: Barcelona
country: Spain
facility: Hospital Santa Creu i Sant Pau /ID# 248511
city: Granada
country: Spain
facility: Hospital Universitario Virgen de las Nieves /ID# 248528
city: Granada
country: Spain
facility: Hospital Universitario Clinico San Cecilio /ID# 248530
city: Huelva
country: Spain
facility: Hospital Juan Ramon Jimenez /ID# 251960
city: Jaen
country: Spain
facility: Hospital Universitario de Jaen /ID# 251959
city: Lugo
country: Spain
facility: Hospital Universitario Lucus Augusti /ID# 248507
city: Malaga
country: Spain
facility: Hospital Universitario Virgen de la Victoria /ID# 248531
city: Salamanca
country: Spain
facility: Hospital Universitario de Salamanca /ID# 253356
city: Santa Cruz de Tenerife
country: Spain
facility: Hospital Universitario Nuestra Señora de Candelaria /ID# 251961
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocio /ID# 248527
city: Valladolid
country: Spain
facility: Hospital Clinico Universitario de Valladolid /ID# 253355
city: Aarau
country: Switzerland
facility: Kantonsspital Aarau AG /ID# 245517
state: Aargau
city: Buochs
country: Switzerland
facility: Dermatology & Skin Care Clinic /ID# 238348
state: Nidwalden
city: St. Gallen
country: Switzerland
facility: Kantonsspital St. Gallen /ID# 239244
state: Sankt Gallen
city: Weinfelden
country: Switzerland
facility: Haut- und Laserzentrum Weinfelden /ID# 239248
state: Telangana
city: Bellinzona
country: Switzerland
facility: EOC Ospedale Regionale di Bellinzona e Valli /ID# 239246
state: Ticino
city: Orsières
country: Switzerland
facility: Basile Darbellay SA /ID# 239245
state: Valais
city: Zurich
country: Switzerland
facility: University Hospital Zurich /ID# 240076
state: Zuerich
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 244758
state: Keelung
city: Taichung
country: Taiwan
facility: Chung Shan Medical University Hospital /ID# 244757
state: Keelung
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital /ID# 244754
state: Taipei
city: Taipei City
country: Taiwan
facility: Chang Gung Memorial Foundation-Taipei Branch /ID# 244760
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hosp /ID# 244759
city: Taoyuan City
country: Taiwan
facility: Linkou Chang Gung Memorial Hospital /ID# 244756
city: Abu Dhabi
country: United Arab Emirates
facility: New Medical Center Hospital /ID# 245106
city: Abu Dhabi
country: United Arab Emirates
facility: Tawam Hospital /ID# 249696
city: Dubai
country: United Arab Emirates
facility: Safa Clinic /ID# 248492
Study officials:
affiliation: AbbVie
name: ABBVIE INC.
role: STUDY_DIRECTOR
References: